Pharma Business - April 10, 2019
AstraZeneca’s Lynparza approved in EU
AstraZeneca and MSD have announced that the European Commission has approved Lynparza (olaparib) as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations (gBRCAm), and who have human epidermal growth factor receptor 2 (HER2)-negative locally-advanced or metastatic breast cancer. “With this approval, Lynparza provides patients throughout the EU with a targeted and oral chemotherapy-free treatment option […]
Pharma Business - March 4, 2019
AstraZeneca’s Lynparza receives positive EU opinion
AstraZeneca and MSD have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the use of Lynparza (olaparib) tablets as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have human epidermal growth factor receptor 2 (HER2)-negative locally advanced or […]
Clinical Trials - May 23, 2016
AZ provides positive results from Lynparza trial
AstraZeneca has announced that Lynparza (olaparib) in combination with paclitaxel chemotherapy, compared with paclitaxel chemotherapy alone, did not meet the primary endpoint of overall survival (OS) in the Phase III GOLD trial in advanced gastric cancer patients, in either the overall population or patients whose tumour tested negative for Ataxia-Telangectasia Mutated (ATM) protein. Whilst there […]
